Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Prostate Cancer

  Free Subscription


Articles published in Clin Cancer Res

Retrieve available abstracts of 67 articles:
HTML format
Text format



Single Articles


    November 2017
  1. BELDERBOS BPS, Bins S, van Leeuwen RWF, Oomen-de Hoop E, et al
    Influence of Enzalutamide on Cabazitaxel Pharmacokinetics; a Drug-Drug Interaction Study in Metastatic Castration Resistant Prostate Cancer (mCRPC) Patients.
    Clin Cancer Res. 2017 Nov 17. pii: clincanres.2336.2017.
    PubMed     Text format     Abstract available


  2. ZHANG W, Liu B, Wu W, Li L, et al
    Targeting the MYCN-PARP-DNA Damage Response Pathway inNeuroendocrine Prostate Cancer.
    Clin Cancer Res. 2017 Nov 14. pii: clincanres.1872.2017.
    PubMed     Text format     Abstract available


  3. PALLER CJ, Zhou XC, Heath EI, Taplin ME, et al
    Muscadine Grape Skin Extract in Men with Biochemically Recurrent Prostate Cancer: A Randomized, Multicenter, Placebo-Controlled Clinical Trial.
    Clin Cancer Res. 2017 Nov 7. pii: clincanres.1100.2017.
    PubMed     Text format     Abstract available


    September 2017
  4. KALINA JL, Neilson DS, Lin YY, Hamilton PT, et al
    Mutational Analysis of Gene Fusions Predicts Novel MHC Class I-Restricted T cell Epitopes & Immune Signatures in a Subset of Prostate Cancer.
    Clin Cancer Res. 2017 Sep 27. pii: clincanres.0618.2017.
    PubMed     Text format     Abstract available


  5. LABBE DP, Sweeney CJ, Brown M, Galbo P, et al
    TOP2A and EZH2 provide early detection of an aggressive prostate cancer subgroup.
    Clin Cancer Res. 2017 Sep 12. pii: clincanres.0413.2017.
    PubMed     Text format     Abstract available


  6. KETOLA K, Munuganti RS, Davies A, Nip KM, et al
    Targeting Prostate Cancer Subtype 1 by Forkhead box M1 Pathway Inhibition.
    Clin Cancer Res. 2017 Sep 12. pii: clincanres.0901.2017.
    PubMed     Text format     Abstract available


  7. CALAGUA C, Russo J, Sun Y, Schaefer R, et al
    Expression of PD-L1 in Hormone-naive and Treated Prostate Cancer Patients Receiving Neoadjuvant Abiraterone Acetate plus Prednisone and Leuprolide.
    Clin Cancer Res. 2017 Sep 11. pii: clincanres.0807.2017.
    PubMed     Text format     Abstract available


    August 2017
  8. BELTRAN H, Wyatt AW, Chedgy E, Donoghue A, et al
    Impact of therapy on genomics and transcriptomics in high-risk prostate cancer treated with neoadjuvant docetaxel and androgen deprivation therapy.
    Clin Cancer Res. 2017 Aug 25. pii: clincanres.1034.2017.
    PubMed     Text format     Abstract available


  9. GUEDES L, Antonarakis ES, Schweizer MT, Mirkheshti N, et al
    MSH2 Loss in Primary Prostate Cancer.
    Clin Cancer Res. 2017 Aug 8. pii: clincanres.0955.2017.
    PubMed     Text format     Abstract available


    July 2017
  10. GAO WQ, Guo Y, Zhang K, Cheng C, et al
    Numb-/low enriches a castration resistant prostate cancer cell subpopulation associated with enhanced Notch and Hedgehog signaling.
    Clin Cancer Res. 2017 Jul 27. pii: clincanres.0913.2017.
    PubMed     Text format     Abstract available


  11. SEED G, Yuan W, Mateo J, Carreira S, et al
    Gene Copy Number Estimation From Targeted Next Generation Sequencing Of Prostate Cancer Biopsies: Analytic Validation and Clinical Qualification.
    Clin Cancer Res. 2017 Jul 27. pii: clincanres.0972.2017.
    PubMed     Text format     Abstract available



  12. Retraction: GRM1 is An Androgen-Regulated Gene and its Expression Correlates with Prostate Cancer Progression in Pre-Clinical Models.
    Clin Cancer Res. 2017;23:3973.
    PubMed     Text format    



  13. Correction: A Phase II Trial of Abiraterone Combined with Dutasteride for Men with Metastatic Castration-Resistant Prostate Cancer.
    Clin Cancer Res. 2017;23:3970.
    PubMed     Text format    


    June 2017
  14. BILUSIC M, Madan RA, Gulley JL
    Immunotherapy of Prostate Cancer: Facts and Hopes.
    Clin Cancer Res. 2017 Jun 29. pii: clincanres.0019.2017.
    PubMed     Text format     Abstract available


  15. XU L, Mao X, Guo T, Chan PY, et al
    The novel association of circulating tumor cells and circulating megakaryocytes with prostate cancer prognosis.
    Clin Cancer Res. 2017 Jun 14. pii: clincanres.3081.2016.
    PubMed     Text format     Abstract available


    May 2017
  16. BAN K, Feng S, Shao L, Ittmann M, et al
    RET signaling in prostate cancer.
    Clin Cancer Res. 2017 May 10. pii: clincanres.0528.2017.
    PubMed     Text format     Abstract available


  17. KOHLI M, Ho Y, Hillman DW, Van Etten JL, et al
    Androgen receptor variant AR-V9 is co-expressed with AR-V7 in prostate cancer metastases and predicts abiraterone resistance.
    Clin Cancer Res. 2017 May 4. pii: clincanres.0017.2017.
    PubMed     Text format     Abstract available


    April 2017
  18. GUEDES L, Almutairi F, Haffner MC, Rajoria G, et al
    Analytic, Pre-analytic and Clinical Validation of p53 Immunohistochemistry for Detection of TP53 Missense Mutation in Prostate Cancer.
    Clin Cancer Res. 2017 Apr 26. pii: clincanres.0257.2017.
    PubMed     Text format     Abstract available


  19. MOSTAGHEL EA, Cho E, Zhang A, Alyamani M, et al
    Association of Tissue Abiraterone Levels and SLCO Genotype with Intraprostatic Steroids and Pathologic Response in Men with High-Risk Localized Prostate Cancer.
    Clin Cancer Res. 2017 Apr 7. pii: clincanres.2245.2016.
    PubMed     Text format     Abstract available


    March 2017
  20. SUOMINEN MI, Fagerlund KM, Rissanen JP, Konkol YM, et al
    Radium-223 inhibits osseous prostate cancer growth by dual targeting of cancer cells and bone microenvironment in mouse models.
    Clin Cancer Res. 2017 Mar 31. pii: clincanres.2955.2016.
    PubMed     Text format     Abstract available


    February 2017
  21. RATHKOPF DE, Antonarakis ES, Shore ND, Tutrone RF, et al
    Safety and Antitumor Activity of Apalutamide (ARN-509) in Metastatic Castration-Resistant Prostate Cancer with and without Prior Abiraterone Acetate and Prednisone.
    Clin Cancer Res. 2017 Feb 17. pii: clincanres.2509.2016.
    PubMed     Text format     Abstract available


  22. SAXENA R, Yang C, Rao M, Turaga RC, et al
    Preclinical development of a non-toxic oral formulation of monoethanolamine, a lipid precursor, for prostate cancer treatment.
    Clin Cancer Res. 2017 Feb 6. pii: clincanres.1716.2016.
    PubMed     Text format     Abstract available


    January 2017
  23. WANG R, Wang J, Gao G, Hu J, et al
    Pre-biopsy mp-MRI can help to improve the predictive performance in prostate cancer: a prospective study in 1478 consecutive patients.
    Clin Cancer Res. 2017 Jan 31. pii: clincanres.2884.2016.
    PubMed     Text format     Abstract available


  24. KIM K, Zhang H, LaRosa S, Jebiwott S, et al
    Bombesin Antagonist Based Radiotherapy of Prostate Cancer Combined with WST-11 Vascular Targeted Photodynamic Therapy.
    Clin Cancer Res. 2017 Jan 20. pii: clincanres.2745.2016.
    PubMed     Text format     Abstract available


  25. CASTIELLO L, Sabatino M, Ren J, Terabe M, et al
    Expression of CD14, IL-10 and tolerogenic signature in dendritic cells inversely correlate with response to TARP vaccination in prostate cancer patients.
    Clin Cancer Res. 2017 Jan 10. pii: clincanres.2199.2016.
    PubMed     Text format     Abstract available



  26. Correction: Niclosamide Inhibits Androgen Receptor Variants Expression and Overcomes Enzalutamide Resistance in Castration-Resistant Prostate Cancer.
    Clin Cancer Res. 2017;23:323.
    PubMed     Text format    


    December 2016
  27. LAM HM, McMullin R, Nguyen H, Coleman I, et al
    Characterization of an abiraterone ultraresponsive phenotype in castration-resistant prostate cancer patient-derived xenografts.
    Clin Cancer Res. 2016 Dec 19. pii: clincanres.2054.2016.
    PubMed     Text format     Abstract available


    November 2016
  28. ANTONARAKIS ES, Kibel AS, Yu EY, Karsh LI, et al
    Sequencing of Sipuleucel-T and Androgen Deprivation Therapy in Men with Hormone-Sensitive Biochemically-Recurrent Prostate Cancer: A Phase II Randomized Trial.
    Clin Cancer Res. 2016 Nov 10. pii: clincanres.1780.2016.
    PubMed     Text format     Abstract available


  29. YIN Y, Zhang Q, Zhang H, He Y, et al
    Molecular signature to risk-stratify prostate cancer of intermediate risk.
    Clin Cancer Res. 2016 Nov 1. pii: clincanres.2400.2016.
    PubMed     Text format     Abstract available


    October 2016
  30. PENET MF, Kakkad S, Pathak AP, Krishnamachary B, et al
    Structure and Function of a Prostate Cancer Dissemination Permissive Extracellular Matrix.
    Clin Cancer Res. 2016 Oct 31. pii: clincanres.1516.2016.
    PubMed     Text format     Abstract available


  31. SAYYID R, Evans A, Hersey K, Maloni R, et al
    A Phase II, Randomized, Open Label Study of Neoadjuvant Degarelix versus LHRH Agonist in Prostate Cancer Patients Prior to Radical Prostatectomy.
    Clin Cancer Res. 2016 Oct 18. pii: clincanres.1790.2016.
    PubMed     Text format     Abstract available


  32. PALAPATTU GS, Salami SS, Cani AK, Hovelson DH, et al
    Molecular Profiling to Determine Clonality of Serial Magnetic Resonance Imaging/Ultrasound Fusion Biopsies from Men on Active Surveillance for Low-Risk Prostate Cancer.
    Clin Cancer Res. 2016 Oct 7. doi: 10.1158/1078-0432.CCR-16-1454.
    PubMed     Text format     Abstract available


  33. KUHN P, Carlsson A, Luttgen MS, Dizon KK, et al
    Paired high-content analysis of prostate cancer cells in bone marrow and blood characterizes increased androgen receptor expression in tumor cell clusters.
    Clin Cancer Res. 2016 Oct 4. pii: clincanres.1355.2016.
    PubMed     Text format     Abstract available


    September 2016
  34. TAPLIN ME, McKay RR, Werner L, Mostaghel EA, et al
    A phase II trial of abiraterone combined with dutasteride for men with metastatic castration-resistant prostate cancer.
    Clin Cancer Res. 2016 Sep 28. pii: clincanres.0987.2016.
    PubMed     Text format     Abstract available


  35. BRAGELMANN J, Klumper N, Offermann A, von Massenhausen A, et al
    Pan-cancer analysis of the Mediator complex transcriptome identifies CDK19 and CDK8 as therapeutic targets in advanced prostate cancer.
    Clin Cancer Res. 2016 Sep 27. pii: clincanres.0094.2016.
    PubMed     Text format     Abstract available


  36. HELLER G, Fizazi K, McCormack RT, Molina A, et al
    The added value of circulating tumour cell enumeration to standard markers in assessing prognosis in a metastatic castration-resistant prostate cancer population.
    Clin Cancer Res. 2016 Sep 27. pii: clincanres.1224.2016.
    PubMed     Text format     Abstract available


  37. LUK IS, Shrestha R, Xue H, Wang Y, et al
    BIRC6-targeting as potential therapy for advanced, enzalutamide-resistant prostate cancer.
    Clin Cancer Res. 2016 Sep 23. pii: clincanres.0718.2016.
    PubMed     Text format     Abstract available


  38. GUPTA S, Li J, Kemeny G, Bitting RL, et al
    Whole genomic copy number alterations in circulating tumor cells from men with abiraterone or enzalutamide resistant metastatic castration-resistant prostate cancer.
    Clin Cancer Res. 2016 Sep 6. pii: clincanres.1211.2016.
    PubMed     Text format     Abstract available


    August 2016
  39. QU F, Xie W, Nakabayashi M, Zhang H, et al
    Association of AR-V7 and prostate specific antigen RNA levels in blood with efficacy of abiraterone acetate and enzalutamide treatment in men with prostate cancer.
    Clin Cancer Res. 2016 Aug 3. pii: clincanres.1070.2016.
    PubMed     Text format     Abstract available


  40. REBELLO RJ, Kusnadi E, Cameron DP, Pearson HB, et al
    The dual inhibition of RNA Pol I transcription and PIM kinase as a new therapeutic approach to treat advanced prostate cancer.
    Clin Cancer Res. 2016 Aug 2. pii: clincanres.0124.2016.
    PubMed     Text format     Abstract available


    July 2016
  41. SHOURIDEH M, Azabdaftari G, Attwood K, DePriest A, et al
    GRM1 is An Androgen-Regulated Gene and its Expression Correlates with Prostate Cancer Progression in Pre-Clinical Models.
    Clin Cancer Res. 2016 Jul 25. pii: clincanres.0137.2016.
    PubMed     Text format     Abstract available


  42. SAYLOR PJ, Lee RJ, Arora KS, Deshpande V, et al
    Branched chain RNA in situ hybridization for androgen receptor splice variant AR-V7 as a prognostic biomarker for metastatic castration-sensitive prostate cancer.
    Clin Cancer Res. 2016 Jul 20. pii: clincanres.0237.2016.
    PubMed     Text format     Abstract available



  43. Correction: Absolute Effect of Prostate Cancer Screening: Balance of Benefits and Harms by Center within the European Randomized Study of Prostate Cancer Screening.
    Clin Cancer Res. 2016;22:3702.
    PubMed     Text format    


    June 2016
  44. ZHAO S, Geybels MS, Leonardson A, Rubicz R, et al
    Epigenome-wide Tumor DNA Methylation Profiling Identifies Novel Prognostic Biomarkers of Metastatic-lethal Progression in Men with Clinically Localized Prostate Cancer.
    Clin Cancer Res. 2016 Jun 29. pii: clincanres.0549.2016.
    PubMed     Text format     Abstract available


  45. SHARP A, Welti J, Blagg J, de Bono JS, et al
    Targeting Androgen Receptor Aberrations in Castration-Resistant Prostate Cancer.
    Clin Cancer Res. 2016 Jun 21. pii: clincanres.1137.2016.
    PubMed     Text format     Abstract available


  46. BANSAL N, Bartucci M, Yusuff S, Davis S, et al
    BMI-1 targeting interferes with patient-derived tumor-initiating cell survival and tumor growth in prostate cancer.
    Clin Cancer Res. 2016 Jun 15. pii: clincanres.3107.2015.
    PubMed     Text format     Abstract available


  47. YAMIN G, Schenker-Ahmed NM, Shabaik A, Adams D, et al
    Voxel Level Radiologic-Pathologic Validation of Restriction Spectrum Imaging Cellularity Index with Gleason Grade in Prostate Cancer.
    Clin Cancer Res. 2016;22:2668-74.
    PubMed     Text format     Abstract available


    May 2016
  48. GUEDES L, Morais C, Almutairi F, Haffner MC, et al
    Analytic Validation of RNA In Situ Hybridization (RISH) for AR and AR-V7 Expression in Human Prostate Cancer.
    Clin Cancer Res. 2016 May 10. pii: clincanres.0205.2016.
    PubMed     Text format     Abstract available


  49. YANG YC, Banuelos CA, Mawji NR, Wang J, et al
    Targeting androgen receptor activation function-1 with EPI to overcome resistance mechanisms in castration-resistant prostate cancer.
    Clin Cancer Res. 2016 May 2. pii: clincanres.2901.2015.
    PubMed     Text format     Abstract available


    April 2016
  50. CHEN X, Li Q, Liu X, Liu C, et al
    Defining a population of stem-like human prostate cancer cells that can generate and propagate castration-resistant prostate cancer (CRPC).
    Clin Cancer Res. 2016 Apr 8. pii: clincanres.2956.2015.
    PubMed     Text format     Abstract available


    March 2016
  51. LOPEZ SM, Agoulnik AI, Zhang M, Peterson LE, et al
    Nuclear Receptor Corepressor 1 expression and output declines with prostate cancer progression.
    Clin Cancer Res. 2016 Mar 11. pii: clincanres.1983.2015.
    PubMed     Text format     Abstract available


  52. GAO S, Ye H, Gerrin S, Wang H, et al
    ErbB2 Signaling Increases Androgen Receptor Expression in Abiraterone-Resistant Prostate Cancer.
    Clin Cancer Res. 2016 Mar 2. pii: clincanres.2309.2015.
    PubMed     Text format     Abstract available


    February 2016
  53. MORRIS MJ, Rathkopf DE, Novotny W, Gibbons JA, et al
    Phase Ib Study of Enzalutamide in Combination with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer.
    Clin Cancer Res. 2016 Feb 8. pii: clincanres.2638.2015.
    PubMed     Text format     Abstract available


  54. HUSSAIN M, Le Moulec S, Gimmi C, Bruns R, et al
    Differential Effect on Bone Lesions of Targeting Integrins: Randomized Phase II Trial of Abituzumab in Patients with Metastatic Castration-resistant Prostate Cancer.
    Clin Cancer Res. 2016 Feb 2. pii: clincanres.2512.2015.
    PubMed     Text format     Abstract available


  55. HEDAYATI M, Haffner MC, Coulter J, Raval RR, et al
    Androgen deprivation followed by acute androgen stimulation selectively sensitizes AR-positive prostate cancer cells to ionizing radiation.
    Clin Cancer Res. 2016 Feb 1. pii: clincanres.1147.2015.
    PubMed     Text format     Abstract available


    January 2016
  56. LENNARTZ M, Minner S, Brasch S, Wittmann H, et al
    The combination of DNA ploidy status and PTEN/6q15 deletions provides strong and independent prognostic information in prostate cancer.
    Clin Cancer Res. 2016 Jan 26. pii: clincanres.0635.2015.
    PubMed     Text format     Abstract available


  57. CHOI SY, Xue H, Wu R, Fazli L, et al
    The MCT4 Gene: a Novel, Potential Target for Therapy of Advanced Prostate Cancer.
    Clin Cancer Res. 2016 Jan 11. pii: clincanres.1624.2015.
    PubMed     Text format     Abstract available



  58. Retraction: Suppression of N-Methyl-N-nitrosourea/Testosterone-Induced Rat Prostate Cancer Growth by Celecoxib: Effects on Cyclooxygenase-2, Cell Cycle Regulation, and Apoptosis Mechanism(s).
    Clin Cancer Res. 2016;22:270.
    PubMed     Text format    


  59. HABERKORN U, Eder M, Kopka K, Babich JW, et al
    New Strategies in Prostate Cancer: Prostate-Specific Membrane Antigen (PSMA) Ligands for Diagnosis and Therapy.
    Clin Cancer Res. 2016;22:9-15.
    PubMed     Text format     Abstract available


    December 2015
  60. ZHANG W, Yi B, Wang C, Chen D, et al
    Silencing of CD24 enhances the PRIMA-1-induced restoration of mutant p53 in prostate cancer cells.
    Clin Cancer Res. 2015 Dec 28. pii: clincanres.1927.2015.
    PubMed     Text format     Abstract available


  61. VAN LEEUWEN FW, van der Poel HG
    Surgical Guidance in Prostate Cancer: "From Molecule to Man" Translations.
    Clin Cancer Res. 2015 Dec 28. pii: clincanres.2575.2015.
    PubMed     Text format     Abstract available


  62. KATO M, Banuelos CA, Imamura Y, Leung JK, et al
    Co-targeting Androgen Receptor Splice Variants and mTOR signaling pathway for the Treatment of Castration-Resistant Prostate Cancer.
    Clin Cancer Res. 2015 Dec 28. pii: clincanres.2119.2015.
    PubMed     Text format     Abstract available


  63. BELTRAN H, Jendrisak A, Landers M, Mosquera JM, et al
    The Initial Detection and Partial Characterization of Circulating Tumor Cells in Neuroendocrine Prostate Cancer.
    Clin Cancer Res. 2015 Dec 15. pii: clincanres.0137.2015.
    PubMed     Text format     Abstract available


  64. ZHAO SG, Evans JR, Kothari V, Sun G, et al
    The landscape of prognostic outlier genes in high-risk prostate cancer.
    Clin Cancer Res. 2015 Dec 2. pii: clincanres.1250.2015.
    PubMed     Text format     Abstract available


    November 2015
  65. GEVENSLEBEN H, Dietrich D, Golletz C, Steiner S, et al
    The immune checkpoint regulator PD-L1 is highly expressed in aggressive primary prostate cancer.
    Clin Cancer Res. 2015 Nov 16. pii: clincanres.2042.2015.
    PubMed     Text format     Abstract available


  66. MEHRA N, Zafeiriou Z, Lorente D, Terstappen LW, et al
    CCR 20th Anniversary Commentary: Circulating Tumor Cells in Prostate Cancer.
    Clin Cancer Res. 2015;21:4992-5.
    PubMed     Text format     Abstract available


    March 2015
  67. SHARIFI N
    Steroid sidestep: evading androgen ablation by abiraterone.
    Clin Cancer Res. 2015;21:1240-2.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: